Omeros Corporation Reports First Quarter 2026 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: First Quarter and Recent Highlights In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million. Net income for the first quarter of.

16.04.2026

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The J-code will become effective July 1, 2026. “For patients with TA-TMA, access to e.

31.03.2026

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $1.

21.03.2026

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,” will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôp.

Omeros Corporation (OMER)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Omeros Corporation (OMER)

Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

Omeros Q1 Earnings Call Highlights

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

Videolar

No Data

Press-relizlar

Omeros Corporation Reports First Quarter 2026 Financial Results

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

Omeros Q1 Earnings Call Highlights

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

Videolar

No Data

Press-relizlar

Omeros Corporation Reports First Quarter 2026 Financial Results

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Search stocks

Omeros Corporation (OMER)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Omeros Corporation (OMER)

Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

Omeros Q1 Earnings Call Highlights

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

Videolar

No Data

Press-relizlar

Omeros Corporation Reports First Quarter 2026 Financial Results

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now

Omeros Q1 Earnings Call Highlights

Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript

Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

Videolar

No Data

Press-relizlar

Omeros Corporation Reports First Quarter 2026 Financial Results

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment